

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-131)

TABELECLEUCEL

PRONUNCIATION

tab" el lek loo' sel

THERAPEUTIC CLAIM

Treatment of patients with Epstein-Barr Virus-associated Post Transplant Lymphoproliferative Disorder in the allogeneic hematopoietic cell transplant and solid organ transplant settings who have failed rituximab

DESCRIPTION

Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs, ATA129) are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-PTLD. EBV-CTLs have been generated from high resolution human leukocyte antigen (HLA)-typed EBV seropositive unrelated third-party T cells and are cryopreserved. EBV-CTLs exhibit HLA-restricted cytotoxic activity against EBV+ but not EBV- target cells and lack alloreactivity. This therapy can be provided off-the-shelf when required by allogeneic hematopoietic cell transplant (alloHCT) or solid organ transplant (SOT) patients who have developed EBV post transplant lymphoproliferative disease (PTLD) and have failed rituximab.

TRADEMARK

None as yet

SPONSOR

Atara Biotherapeutics

CODE DESIGNATION

EBV-CTL, ATA129

WHO NUMBER

10640

SCS